289 / 1708
SIOP 1
•
1975-1979
•
286 patients with medulloblastoma, 45 patients
with ependymoma
•
Randomisation between RT alone and RT
followed by VCR/CCNU for 1 year
•
Overall survival 53% at 5 years, 45% at 10 years
•
At close of trial survival advantage for
chemotherapy (p=0.005), which was later lost
owing to late relapses
➢
Tait DM et al, Eur J Cancer 1990; 26: 464-469